BC

Bablu Chauhan

Active Director Director DIN 10642924
DIN 10642924 First appointment May 2024 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Bablu Chauhan

Data last updated:

Bablu Chauhan is a Director at Zodichem Pharmaceuticals Private Limited (since 2024). The company operates in Pharma.

DIN 10642924
Primary Designation Director
Industry Pharma
First Appointment 24 May 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director24 May 20242024Active

Board colleagues of Bablu Chauhan

NameDINCompanyDesignation
Baban Singh11427942Zodichem Pharmaceuticals Private LimitedAdditional Director
Chandrakala Devi11383839Zodichem Pharmaceuticals Private LimitedAdditional Director

Directorship timeline

Open interactive timeline →
Zodichem Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Bablu Chauhan

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Bablu Chauhan

Bablu Chauhan currently holds 1 directorship: Zodichem Pharmaceuticals Private Limited (Director, since 24 May 2024).

Bablu Chauhan was first appointed on 24 May 2024 as Director at Zodichem Pharmaceuticals Private Limited.

The current boards of Bablu Chauhan's companies include Baban Singh (Zodichem Pharmaceuticals Private Limited), Chandrakala Devi (Zodichem Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available